ACCP has been invited to submit a list of members to be considered for the interprofessional writing panels of two national treatment guidelines. The selected members will serve as the College’s representatives to provide both their therapeutic expertise and their perspectives as clinical pharmacists. Earlier this year, ACCP was invited by the American Heart Association/American College of Cardiology (AHA/ACC) Joint Committee on Clinical Practice Guidelines to participate in developing its upcoming guideline on chronic coronary diseases. Barbara S. Wiggins, Pharm.D., FCCP, FACC, FNLA, FAHA, BCPS, CLS, was selected by the AHA/ACC Joint Committee to serve as ACCP’s representative to the writing panel. One or more additional ACCP members from the list will be selected as reviewers. Wiggins is a clinical pharmacy specialist in cardiology at the Medical University of South Carolina and an affiliate professor at the South Carolina College of Pharmacy. She has been an author of previous AHA/ACC guidelines and served as a member of the Cardiovascular Expert Panel for the United States Pharmacopeia. She is a past chair of the Cardiology PRN and has served as a member on several ACCP committees as well as a reviewer for abstracts submitted for presentation at ACCP meetings and publication in Pharmacotherapy. In addition, she is coeditor of The Pharmacist’s Guide to Lipid Management, Second Edition, published by ACCP.

ACCP was recently invited by the NIH to submit names of members with expertise in pediatric infectious diseases for inclusion on the NIH COVID-19 Treatment Guidelines. Steve Grapentine, Pharm.D., BCPS, APP, was selected as ACCP’s representative to the panel. Grapentine is an assistant clinical professor and pediatric infectious disease pharmacist at the University of California San Francisco Benioff Children’s Hospital and serves as co-lead of its antimicrobial stewardship program. Grapentine is a longstanding member of the ACCP Pediatrics and Infectious Diseases PRNs. He recently served as a member of the writing panel for two guidelines published by the Pediatric Infectious Diseases Society: “Multicenter Initial Guidance on Use of Antivirals for Children with Coronavirus Disease 2019/Severe Acute Respiratory Syndrome Coronavirus 2” (https://doi.org/10.1093/jpids/piaa045) and “Initial Guidance on Use of Monoclonal Antibody Therapy for Treatment of Coronavirus Disease 2019 in Children and Adolescents” (https://doi.org/10.1093/jpids/piaa175).

We congratulate Barbara and Steve on their appointments and encourage all ACCP members with the commensurate therapeutic expertise to apply to the Member Expertise/Guideline Database. The application can be found on your accp.com account under “My Links.”